The MIND Foundation is a European non-profit science and education organization that promotes psychedelic research and therapy. Their work builds on the neurobiological and psychological potential of psychedelics to improve mental health and well-being in a clinical setting.
The MIND Foundation’s INSIGHT conference is at the forefront of psychedelic research in medicine and society and they met this September including clinicians, entrepreneurs, patients and artists, journalists, regulators, and newcomers to the field and seniors to ‘rethink psychedelics’, exploring topics such as non-clinical forms of psychedelic drug use, mindfulness, the philosophy of psychedelic experience, psychedelics in art, as well as patient and therapist spiritualities and more, the conference also facilitated learning from indigenous communities.
David Olson, Director of the Institute for Psychedelics and Neurotherapeutics at UC Davis, as well as Co-Founder and Chief Innovation Officer at Delix Therapeutics, presented the talk ‘Bridging the Gap Between Basic Science and Clinical Research in Psychedelic Neuroscience’.
Olson discussed his group’s work in his academic laboratory which is interested in finding new treatments for stress-related neuropsychiatric diseases, such as depression and PTSD.
This is all promising for the future of Psychedelic Nursing.
